Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01099423 |
|
Recruitment Status : Unknown
Verified February 2017 by European Organisation for Research and Treatment of Cancer - EORTC.
Recruitment status was: Active, not recruiting
First Posted : April 7, 2010
Last Update Posted : February 8, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib malate before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving sunitinib malate after surgery may kill any tumor cells that remain after surgery. It is not yet known whether undergoing immediate surgery or surgery after sunitinib malate is more effective in treating patients with metastatic kidney cancer.
PURPOSE: This randomized phase III trial is studying immediate surgery to see how well it works compared with surgery after sunitinib malate in treating patients with metastatic kidney cancer.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Kidney Cancer | Procedure: timing of surgery Genetic: gene expression analysis Other: biologic sample preservation procedure Other: laboratory biomarker analysis Procedure: therapeutic conventional surgery | Phase 3 |
OBJECTIVES:
- To determine if immediate versus deferred nephrectomy has an effect on disease control in patients with resectable, synchronous, metastatic renal cell carcinoma treated with sunitinib malate.
- To identify potential response criteria based on histopathology and molecular research on tumor tissue.
OUTLINE: This is a multicenter study. Patients are stratified according to WHO performance status (0 vs 1), number of metastatic sites (1 vs 2 or more), and institution. Patients are randomized to 1 of 2 treatment arms.
- Arm I (immediate nephrectomy): Patients undergo cytoreductive nephrectomy. Beginning 4 weeks after surgery, patients receive oral sunitinib malate once daily on days 1-28. Treatment with sunitinib malate repeats every 6 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
- Arm II (deferred nephrectomy): Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. About 1 day after completion of sunitinib malate, patients undergo cytoreductive nephrectomy. Patients then receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
Some patients undergo tumor tissue collection at baseline and at time of surgery to assess possible differences in gene expression. Patients also undergo blood sample collection periodically to evaluate the potential impact of serum proteins on the clinical outcome. Samples are then stored for future studies.
After completion of study treatment, patients are followed periodically.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 99 participants |
| Allocation: | Randomized |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Randomized Phase III Trial Comparing Immediate Versus Deferred Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma |
| Actual Study Start Date : | April 2010 |
| Actual Primary Completion Date : | April 2016 |
| Estimated Study Completion Date : | May 2017 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Immediate nephrectomy
Surgery followed by Sunitinib
|
Genetic: gene expression analysis Other: biologic sample preservation procedure Other: laboratory biomarker analysis Procedure: therapeutic conventional surgery |
|
Experimental: Deferred nephrectomy
Sunitinib (3 cycles) followed by surgery followed by Sunitinib
|
Procedure: timing of surgery Genetic: gene expression analysis Other: biologic sample preservation procedure Other: laboratory biomarker analysis |
- Overall progression-free survival
- Overall survival
- Morbidity
- Overall response to treatment in the deferred nephrectomy arm including the proportion of patients who become unresectable
- Effect of nephrectomy on early progression in both arms
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 120 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
-
Histologically confirmed renal cell cancer (RCC)
-
Clear-cell subtype with a resectable asymptomatic in situ primary
- Asymptomatic primary is defined as the absence of symptoms* which can be exclusively assigned to the primary tumor such as flank pain and/or gross hematuria necessitating blood transfusion NOTE: *Para-neoplastic symptoms cannot be assigned to the primary tumor alone in metastatic disease, they are not included in this definition.
- No symptomatic primary tumor necessitating nephrectomy
-
-
Resectable primary tumor
- Bulky locoregional lymph node metastases larger than the primary tumor allowed provided resectability of the lymph nodes is surgically feasible
-
Metastatic RCC
- Distant metastases are not completely resectable at the time of surgery or during an additional intervention
- No multiple distant lesions at one site
- No bone-only metastases
- Measurable disease, both primary and metastatic, according to RECIST 1.1 criteria
- Planning to receive sunitinib malate as background therapy
-
Patients with > 3 of the following surgical risk factors are not eligible:
- Serum albumin CTCAE v 4.0 grade 2 or worse
- Serum LDH > 1.5 times upper limit of normal
- Liver metastases
- Symptoms at presentation due to metastases
- Retroperitoneal lymph node involvement
- Supra-diaphragmatic lymph node involvement
- Clinical stage T3 or T4 disease
- No clinical signs of CNS involvement
PATIENT CHARACTERISTICS:
- See Disease Characteristics
- WHO performance status 0-1
- Life expectancy > 3 months
- WBC > 3.0 x 10^9/L
- Platelet count > 100 x 10^9/L
- Hemoglobin > 10.0 g/dL
- PT/PTT or INR ≤ 1.2 times upper limit of normal (ULN)
- Bilirubin ≤ 1.5 times ULN
- ALT ≤ 2.5 times ULN (≤ 5 times ULN if liver lesions)
- Serum calcium < 10.0 mg/dL
- Calculated or measured creatinine clearance > 30 mL/min
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception 2 weeks before and during study treatment
- LVEF normal by MUGA scan or ECHO
- 12-lead ECG normal
- No serious cardiac illness (myocardial infarction and/or treatable or untreatable angina pectoris not responding to treatment) within the past 12 months
- No uncontrolled, high BP (≥ 150/100 mm Hg) despite optimal medical therapy
- No current pulmonary disease
- No active or uncontrolled infections, serious illnesses, malabsorption syndrome, or medical conditions, including patients with a history of chronic alcohol abuse, hepatitis, HIV, and/or cirrhosis
- No malignancies within the past 5 years except renal cell carcinoma, basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, resected incidental prostate cancer staged pT2 with Gleason Score ≤ 6 and postoperative PSA < 0.5 ng/mL, or patients with any history of malignancies who are disease-free for more than 5 years
- No psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
PRIOR CONCURRENT THERAPY:
- Prior local radiotherapy for bone lesions allowed
- No prior systemic therapy for metastatic RCC
- No prior partial or total nephrectomy
- No concurrent systemic corticosteroid and/or other immunosuppressive systemic therapies
- No concurrent radiotherapy, except palliative radiotherapy
- No concurrent participation in another clinical trial testing treatments for any disease including renal cell carcinoma
- No other concurrent investigational or systemic therapy for metastatic RCC
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01099423
Show 29 study locations
| Study Chair: | Axel Bex | The Netherlands Cancer Institute | |
| Study Chair: | John B.A.G. Haanen | The Netherlands Cancer Institute |
| Responsible Party: | European Organisation for Research and Treatment of Cancer - EORTC |
| ClinicalTrials.gov Identifier: | NCT01099423 |
| Other Study ID Numbers: |
EORTC-30073 EU-21022 PFIZER-EORTC-30073 |
| First Posted: | April 7, 2010 Key Record Dates |
| Last Update Posted: | February 8, 2017 |
| Last Verified: | February 2017 |
|
clear cell renal cell carcinoma stage IV renal cell cancer |
|
Kidney Neoplasms Carcinoma, Renal Cell Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site Neoplasms Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications |
Urogenital Diseases Kidney Diseases Urologic Diseases Male Urogenital Diseases Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type |